Regenxbio Inc

NASDAQ:RGNX

8.74

+0.12 (+1.39%)

4:33:16 PM EDT: $8.74 0.00 (0.00%)

Market Cap (Intraday)	446.52M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$38.7 Million
Adjusted EPS	-$0.94

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Regenxbio Inc Stock, NASDAQ:RGNX

9804 Medical Center Drive, Suite 210, Rockville, Maryland 20850

United States of America

Phone: +1.240.552.8181

Number of Employees: 353

http://www.regenxbio.com

Description

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.